window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 13, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Discovery & Development

  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain

    PSI launches AI platform to improve clinical trial site selection and enrolment

    PSI CRO has launched SYNETIC, an AI-powered semantic knowledge platform [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Research finds scientists view ELNs as ‘glorified filing cabinets’, driving duplication and shadow AI use

    A new survey by Sapio Sciences has found widespread frustration [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Opinion & Events

    Kayentis and Ametris partner on integrated eCOA and wearable adherence platform

    Kayentis and Ametris have announced a strategic partnership to integrate [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development,Medical devices,Therapeutic Areas

    En Carta Diagnostics receives FDA breakthrough device designation for Lyme disease test

    En Carta Diagnostics has received FDA Breakthrough Device Designation for [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain

    Spore.Bio appoints Michael Miller as VP of scientific and regulatory affairs

    Spore.Bio has appointed Michael Miller as vp of scientific and [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    TECregen appoints Dr Klaas Zuideveld as CEO to advance thymus regeneration platform

    TECregen has appointed Dr Klaas Zuideveld as chief executive officer [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Skyhawk Therapeutics reports positive nine-month interim results for SKY-0515 in Huntington’s disease

    Skyhawk Therapeutics has reported positive nine-month interim results from its [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    iXCells Biotechnologies partners with Rosebud Biosciences to advance organoid models for rare diseases

    iXCells Biotechnologies and Rosebud Biosciences have announced a partnership to [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Nine-gene signature linked to lapatinib resistance in HER2-positive breast cancer

    Researchers at City St George’s, University of London have identified [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Nanexa targets next-generation ‘fat jab’ with monthly semaglutide delivery platform

    Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide [...]

    May 5, 2026
Previous121314Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Orano Med appoints Frederic Desdouits as CEO to advance targeted alpha therapy pipeline
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Aravax adds allergy specialists to board as peanut therapy advances
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Therapeutic Areas
  • AI-derived drug candidate reduces fentanyl intake in preclinical opioid study
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top